MedTrace Logo

Rechallenge of BRAF +/- MEK Inhibitors Following an Adverse Event in Patients With Cancer

NCT05080361 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 16000

Last updated 2021-10-15

No results posted yet for this study

Summary

Very little data are published on the safety of a rechallenge with a BRAF inhibitor or combination of BRAF and MEK inhibitor (BRAFi and MEKi) after an adverse event (AE). This study aimed at identifying the recurrence rate of the same AE after a BRAFi +/- MEKi rechallenge in patients with cancer and the factors associated to the recurrence.

Conditions

Interventions

DRUG

BRAF inhibitor

Reports of adverse events occurring in patients treated with at least one BRAFi or MEKi as reported in the individual case safety reports.

Sponsors & Collaborators

  • University Hospital, Caen

    lead OTHER

Principal Investigators

  • Charles Dolladille · University Hospital, Caen

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-01
Primary Completion
2021-03-01
Completion
2021-12-01
FDA Drug
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05080361 on ClinicalTrials.gov